alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Insulin-like growth factor 2 receptor (IGF2R), also called the cation-independent mannose-6-phosphate receptor (CI-MPR) is a protein that in humans is encoded by the IGF2R gene. IGF2R is a multifunctional protein receptor that binds insulin-like growth factor 2 (IGF2) at the cell surface and mannose-6-phosphate (M6P)-tagged proteins in the trans-Golgi network.
===== History of Vitatron ===== 1956: Vitatron founded 1962: First Implantable pacemakers 1981: Microprocessor-driven, software-based pacemaker (DPG1) 1982: Rate Responsive pacemaker (TX1) 1984: Quintech DDD with automatic upper rate behavior ("mode switch") 1988: Daily Learn algorithm (Rhythmyx) 1997: First upgradeable pacemaker system with dedicated AF diagnostics, rate and rhythm control therapy. 2003: Vitatron goes digital: 1st Vitatron C-Series, the world's first fully digital pacemaker. 2004: 2nd Vitatron C-Series, digital, fast pacemaker. 2004: Vitatron T-Series: The full picture, digital pacemaker system. 2005: Vitatron C-Series, A3 models, a new top line range of digital pacemakers for bradycardic patients.
==== Monotherapy ==== There are old studies indicating efficacy of lithium for acute depression with lithium having the same efficacy as tricyclic antidepressants. A 2019 systemic review of studies from the 1970s to 2000s found that lithium monotherapy was just as effective as antidepressant monotherapy.
=== Australia === A person conducting a business or undertaking (PCBU—the new term that includes employers) has duties under the work health and safety (WHS) legislation to ensure a worker affected by alcohol or other drugs does not place themselves or other persons at risk of injury while at work. Workplace policies and prevention programs can help change the norms and culture around substance use. All organisations—large and small—can benefit from an agreed policy on alcohol and drug misuse that applies to all workers. Such a policy should form part of an organisations overall health and safety management system. PCBUs are encouraged to establish a policy and procedure, in consultation with workers, to constructively manage alcohol and other drug related hazards in their workplace. A comprehensive workplace alcohol and other drug policy should apply to everyone in the workplace and include prevention, education, counselling and rehabilitation arrangements. In addition, the roles and responsibilities of managers and supervisors should be clearly outlined. All Australian workplace drug testing must comply with Australian standard AS/NZS4308:2008. In Victoria, roadside saliva tests detect drugs that contain:
Sources: en.wikipedia.org
APHL monitors trends in public health laboratory diagnostics, personnel and infrastructure. It uses this data to benchmark against national norms and to define issues of importance to lab practice and policy. APHL also disseminates research findings via issue briefs and communications with federal decision makers, health partners and the laboratory community. Members have access to survey data online, enabling them to leverage this information quickly to identify promising strategies and practices. In an effort to improve laboratory practice, APHL provides free resources, such as tools kits that explain how to: Write a laboratory quality manual Conduct an internal audit Recruit students in STEM fields Deal with laboratory floods In addition to on-demand research and reports, APHL provides continuing education courses to help laboratory scientists keep up with emerging trends, and innovative testing techniques. Training sessions are conducted through conferences, seminars, workshops and online courses.
There are 21 known isotopes of sodium (11Na), ranging from 17Na to 39Na (except for 36Na and 38Na), and five isomers. 23Na is the only stable (and the only primordial) isotope, making sodium a monoisotopic (and mononuclidic) element. Sodium has two radioactive cosmogenic isotopes (22Na, with a half-life of 2.6019 years and 24Na, with a half-life of 14.956 hours). With the exception of those two isotopes, all other isotopes have half-lives under a minute, most under a second. Acute neutron radiation exposure (e.g., from a nuclear criticality accident) converts some of the stable 23Na in human blood plasma to 24Na. The neutron radiation dose absorbed by the patient can be assessed by measuring the concentration of the radioisotope. 22Na is a positron-emitting isotope with a relatively long half-life, about 2.6 years. It is used to create test-objects and point-sources for positron emission tomography.
=== Sandmeyer methodology === The Sandmeyer methodology is the oldest and straightforward way for the synthesis of isatin. The method involves the condensation between chloral hydrate and a primary arylamine (e.g. aniline), in the presence of hydroxylamine hydrochloride, in aqueous sodium sulfate to form an α‐isonitrosoacetanilide. Isolation of this intermediate and subsequent electrophilic cyclization promoted by strong acids (e.g. sulfuric acid) furnishes isatin in >75% yield.
** Indicates an Imperial Fortress † Bermuda and Halifax were linked, under the Commander-in-Chief at Halifax, with units and strength at Bermuda included in figures for Halifax In February 1855 the new Secretary of State for War was additionally commissioned as Secretary at War, thus giving the Secretary of State oversight of the War Office in addition to his own department. The same procedure was followed for each of his successors, until the office of Secretary at War was abolished altogether in 1863. In 1855 the Board of Ordnance was abolished as a result of its perceived poor performance during the Crimean War. This powerful independent body, dating from the 15th century, had been directed by the Master-General of the Ordnance, usually a very senior military officer who (unlike the Secretary at War) was often a member of the Cabinet. The disastrous campaigns of the Crimean War resulted in the consolidation of all administrative duties in 1855 as subordinate to the Secretary of State for War, a Cabinet job. He was not, however, solely responsible for the Army; the Commander-in-Chief had a virtually equal degree of responsibility. This was reduced in theory by the reforms introduced by Edward Cardwell in 1870, which subordinated the Commander-in-Chief to the Secretary for War. In practice, however, a large influence was retained by the conservative Commander-in-Chief Field Marshal Prince George, 2nd Duke of Cambridge, who held the post between 1856 and 1895.
=== Helmholtz === The model dubbed the 'electric double layer' was first introduced by Hermann von Helmholtz. It assumes that a solution is only composed of electrolytes, no reactions occur near the electrode which could transfer electrons, and that the only Van der Waals interactions are present between the ions in solution and the electrode. These interactions arise only due to the charge density associated with the electrode which arises from either an excess or deficiency of electrons at the electrode's surface. To maintain electrical neutrality the charge of the electrode will be balanced by a redistribution of ions close to its surface. The attracted ions thus form a layer balancing the electrode's charge. The closest distance an ion can come to the electrode will be limited to the radius of the ion plus a single solvation sphere around an individual ion. Overall, two layers of charge and a potential drop from the electrode to the edge of the outer layer (outer Helmholtz Plane) are observed. Given the above description, the Helmholtz model is equivalent in nature to an electrical capacitor with two separated plates of charge, for which a linear potential drop is observed at increasing distance from the plates. The Helmholtz model, while a good foundation for the description of the interface does not take into account several important factors: diffusion/mixing in solution, the possibility of adsorption on to the surface and the interaction between solvent dipole moments and the electrode.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.